News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
93,756 Results
Type
Article (11073)
Company Profile (27)
Press Release (82652)
Multimedia
Podcasts (97)
Webinars (13)
Section
Business (35114)
Career Advice (553)
Deals (6074)
Drug Delivery (119)
Drug Development (13019)
Employer Resources (44)
FDA (2058)
Job Trends (2197)
News (51153)
Policy (4907)
Tag
2025 Best Places to Work (2)
2026 Best Places to Work (4)
2027 BioCapital Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 NextGen (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (1)
40 Under 40 (1)
Academia (180)
Accelerated approval (11)
ADA (13)
Adcomms (21)
Allergies (42)
Alliances (8276)
ALS (55)
Alzheimer's disease (351)
Antibody-drug conjugate (ADC) (154)
Approvals (2001)
Artificial intelligence (237)
ASCO (58)
Autoimmune disease (92)
Automation (11)
Bankruptcy (55)
Belgium (6)
Best Places to Work (1214)
BIO (23)
Biologics (16)
BIOSECURE Act (9)
Biosimilars (94)
BioSpace Insights (66)
Biotechnology (14)
Bispecific (7)
Bladder cancer (42)
Brain cancer (12)
Breast cancer (78)
Cancer (1140)
Cardiovascular disease (180)
Career advice (471)
Career pathing (31)
CAR-T (68)
CDC (13)
CDMO (97)
Celiac Disease (1)
Cell-line development (1)
Cell therapy (170)
Cervical cancer (5)
Clinical research (11378)
Collaboration (595)
Commercialization (19)
Company closure (3)
Compensation (136)
Complete response letters (43)
COVID-19 (469)
CRISPR (10)
CRO (3)
C-suite (375)
Cystic fibrosis (17)
Data (1193)
Decentralized trials (2)
Denatured (14)
Depression (44)
Dermatology (45)
Diabetes (140)
Diagnostics (558)
Digital health (14)
Diversity (8)
Diversity, equity & inclusion (11)
Drug discovery (142)
Drug pricing (169)
Drug shortages (25)
Duchenne muscular dystrophy (94)
Earnings (10354)
Editorial (52)
Employer branding (6)
Employer resources (51)
ESMO (35)
Events (12853)
Executive appointments (295)
Eye disease (4)
FDA (2656)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (398)
Gene editing (33)
Generative AI (43)
Gene therapy (153)
GLP-1 (518)
Government (865)
Grass and pollen (1)
Guidances (48)
Healthcare (1564)
Hematology (28)
HIV (19)
Huntington's disease (23)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (23)
Immunology and inflammation (182)
Immuno-oncology (51)
Indications (25)
Infectious disease (569)
Inflammatory bowel disease (50)
Inflation Reduction Act (6)
Influenza (30)
Intellectual property (50)
Interviews (79)
IPO (2145)
IRA (42)
Job creations (850)
Job search strategy (391)
JPM (40)
Kidney cancer (3)
Kidney disease (29)
Labor market (92)
Layoffs (252)
Leadership (35)
Legal (1142)
Licensing (35)
Liver cancer (21)
Longevity (7)
Lung cancer (162)
Lung diease (8)
Lymphoma (101)
Machine learning (17)
Management (24)
Manufacturing (441)
Marketing (8)
MASH (59)
Medical device (419)
Medtech (428)
Mergers & acquisitions (4126)
Metabolic disorders (631)
Middle East (1)
mRNA (65)
Multiple sclerosis (46)
Multispecific (2)
NASH (9)
Netherlands (8)
Neurodegenerative disease (119)
Neuropsychiatric disorders (59)
Neuroscience (805)
Neurotech (1)
NextGen: Class of 2026 (646)
Non-profit (152)
Now hiring (60)
Obesity (444)
Opinion (177)
Ovarian cancer (25)
Pain (83)
Pancreatic cancer (74)
Parkinson's disease (77)
Partnered (12)
Patents (138)
Patient advocacy (1)
Patient recruitment (105)
Patient selection (11)
Peanut (7)
People (10824)
Peptides (5)
Pharmaceutical (12)
Pharmacy benefit managers (22)
Phase 1 (3129)
Phase 2 (5137)
Phase 3 (4440)
Pipeline (2043)
Policy (205)
Postmarket research (291)
Preclinical (1071)
Press Release (5)
Prostate cancer (68)
Psychedelics (35)
Radiopharmaceuticals (100)
Rare diseases (340)
Real estate (980)
Recruiting (23)
Regulatory (4241)
Reports (17)
Research institute (225)
Resumes & cover letters (100)
Rett syndrome (1)
RNA editing (11)
RSV (30)
Schizophrenia (78)
Series A (70)
Series B (49)
Service/supplier (2)
Sickle cell disease (18)
Special edition (25)
Spinal muscular atrophy (46)
Sponsored (10)
Startups (761)
Stem cells (1)
Stomach cancer (11)
Substance use disorders (5)
Supply chain (55)
Switzerland (5)
Tariffs (94)
Tax incentives (1)
The Weekly (81)
Vaccines (232)
Venture capital (100)
Weight loss (361)
Women's health (35)
Women in leadership (1)
Worklife (11)
Date
Today (24)
Last 7 days (136)
Last 30 days (516)
Last 365 days (4838)
2026 (4315)
2025 (4757)
2024 (5241)
2023 (5754)
2022 (8148)
2021 (7673)
2020 (6712)
2019 (5464)
2018 (4377)
2017 (6198)
2016 (5409)
2015 (5391)
2014 (3334)
2013 (2861)
2012 (2888)
2011 (2852)
2010 (2397)
Location
Africa (186)
Alabama (8)
Arizona (19)
Arkansas (1)
Asia (9694)
Australia (829)
California (1531)
Canada (675)
China (422)
Colorado (97)
Connecticut (146)
Delaware (52)
Europe (21258)
Florida (420)
Georgia (14)
Hawaii (1)
Idaho (3)
Illinois (134)
India (68)
Indiana (66)
Iowa (2)
Japan (246)
Kansas (49)
Kentucky (3)
Louisiana (3)
Maryland (251)
Massachusetts (1288)
Michigan (29)
Minnesota (28)
Mississippi (2)
Missouri (4)
Montana (1)
Nebraska (3)
Nevada (12)
New Hampshire (3)
New Jersey (907)
New Mexico (16)
New York (438)
North Carolina (216)
Northern California (630)
Ohio (79)
Oklahoma (1)
Oregon (9)
Pennsylvania (457)
Puerto Rico (20)
Rhode Island (8)
South America (237)
South Carolina (3)
Southern California (751)
Tennessee (18)
Texas (152)
United States (6348)
Utah (26)
Virginia (27)
Washington D.C. (19)
Washington State (206)
West Virginia (1)
Wisconsin (19)
Wyoming (1)
93,756 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Significant stock movers of October: Biohaven climbs, ArriVent dives
A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech’s shares, while a late-stage lung cancer miss battered ArriVent, which failed to rebound even after encouraging early ADC data.
November 2, 2026
·
3 min read
·
Gabrielle Masson
FDA
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
Troriluzole, in development for spinocerebellar ataxia, was rejected nearly a year ago when the FDA took issue with the design of Biohaven’s registrational study. The agency has now agreed to review a new application and render a decision in the first quarter of 2027.
October 22, 2026
·
2 min read
·
Heather McKenzie
Deals
Biohaven could get up to $795M in epilepsy alliance with SK Bio
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.
August 26, 2026
·
2 min read
·
Tristan Manalac
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
September 10, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
October 30, 2026
·
22 min read
Obesity
Biohaven looks to obesity to bounce back from run of clinical and regulatory failures
After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate for obesity.
June 1, 2026
·
5 min read
·
Heather McKenzie
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
January 2, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
August 10, 2026
·
19 min read
Earnings
Pfizer flat in Q3 despite 32% growth for new and acquired products
Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
November 3, 2026
·
2 min read
·
Annalee Armstrong
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
·
2 min read
·
Tristan Manalac
1 of 9,376
Next
